Birth TissueBirth-Tissue Allografts (Amniotic Membrane, Umbilical Cord, Placental Tissue)
Birth tissue — amniotic membrane, umbilical cord, and placental tissue donated after a live birth — is the fastest-growing HCT/P category and the one FDA has prosecuted most aggressively since 2017. What 21 CFR 1271 actually permits, how the 361 / 351 line cuts through the market, and what an honest birth-tissue establishment looks like operationally.
On this page · 4 sections
How does Birth Tissue apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What birth tissue is
Birth tissue is the collective name for amniotic membrane, amniotic fluid, umbilical cord, and placental tissue recovered after a live, planned caesarean delivery from a consenting mother who has been screened as a living tissue donor. It is regulated by FDA as an HCT/P under 21 CFR 1271, but only when it meets the four 1271.10(a) criteria — minimal manipulation, homologous use, not combined with another article, no systemic effect or dependence on metabolic activity of living cells (with the autologous / first-or-second-degree carve-out).
Recovered tissue is processed into a variety of forms: dehydrated or cryopreserved amniotic membrane sheets for ophthalmic and wound care, micronised amniotic-membrane allografts for orthopaedic and podiatric use, umbilical-cord allografts for soft-tissue reconstruction, and umbilical-cord blood for hematopoietic transplantation (a separately-licensed BLA category).
02The 361 / 351 line — where most birth-tissue products fall on the wrong side
FDA has issued more warning letters and untitled letters in the birth-tissue space than in any other HCT/P category since 2017. The recurring pattern: a product marketed as a 361 HCT/P that fails one or more of the 1271.10(a) criteria — usually homologous use (amniotic membrane intended for orthopaedic injection is not 'serving the same basic function in the recipient as in the donor'), often more-than-minimal manipulation (micronised, particulated, or expanded products are usually not minimally manipulated), and sometimes both.
An honest 361 birth-tissue product is narrow: amniotic-membrane sheets for ophthalmic surface reconstruction (homologous — the membrane was a barrier in utero and is a barrier on the eye), amniotic-membrane wound covers for surface wounds (homologous — same barrier function), umbilical-cord allografts for vascular reconstruction. Most other use cases require an IND or BLA.
03Recovery — what a compliant birth-tissue operation looks like
Birth tissue is recovered from a living donor under Subpart C eligibility requirements. The mother is the donor; consent must be informed, documented, and obtained ideally before active labour. Many establishments use a two-step consent — preliminary written consent in the third trimester, confirmation at admission for delivery. Recovery occurs only after a live planned caesarean delivery (vaginal deliveries are generally not used because aseptic recovery is impractical).
- Donor screening — full medical history, sexual contact and behavioural risk screening, infectious-disease testing within the Subpart C windows.
- Maternal IDM panel — minimum: HIV-1/2 (antibody + NAT), HBV (HBsAg + anti-HBc + NAT), HCV (antibody + NAT), syphilis, plus CMV and WNV for viable cellular products.
- Aseptic recovery — recovery technician trained and qualified, sterile field, sterile instruments, transport in validated containers.
- Cord blood collection (if applicable) — concurrent recovery, separate consent, separate processing.
- Chain of custody from delivery room to processing facility with timestamps and signatures.
04Processing and labelling
Birth-tissue processing must remain within the 'minimal manipulation' envelope to preserve 361 status. For amniotic membrane: cleaning, separation from chorion, antibiotic rinse, dehydration or cryopreservation, terminal sterilisation (gamma, e-beam, supercritical CO₂). Cutting to size, mounting on a carrier, packaging in single-use sterile containers — all within minimal manipulation. Decellularisation, particulation below specific size thresholds, and any in vitro expansion typically cross out of 361.
Labelling must include the AATB / ISBT 128 product code, the donation identification number, expiration date, storage conditions, the proper name of the product, and the FDA-required statements for distribution within or across state lines. Marketing claims on the label and in promotional material must stay strictly within the cleared homologous-use indication; non-homologous marketing creates 351-product exposure regardless of how the product was actually processed.
Frequently asked questions
Q.Is cord blood a 361 HCT/P?+
Cord blood units intended for allogeneic, unrelated hematopoietic transplantation are licensed under Section 351 — each cord blood bank holds a BLA for its product. Autologous, first- or second-degree blood-related, and family-banked cord blood is regulated under 1271 plus FDA's specific cord-blood guidance.
Q.Is amniotic fluid an HCT/P?+
Amniotic fluid is FDA-regulated as an HCT/P only when it meets the 1271.10(a) criteria. Most marketed amniotic-fluid injectable products fail homologous use and are therefore unapproved biologics — multiple warning letters since 2018 cover this category.
Q.What about Wharton's jelly?+
Wharton's jelly products (from umbilical cord) have been the target of FDA enforcement actions since 2019 — most marketed products fail minimal manipulation and homologous use simultaneously. FDA has specifically called out Wharton's-jelly injection products for orthopaedic use as unapproved biologics.
Q.Do I need AATB accreditation to operate?+
Not legally required, but in practice required for clinical adoption. AATB has dedicated birth-tissue standards and a Birth Tissue Council that publishes specific guidance on consent, recovery, processing, and labelling.
Q.What's the donor age window?+
Birth-tissue donors are screened against the same Subpart C medical-history and behavioural-risk criteria as any living tissue donor, plus pregnancy-specific screening (gestational diabetes, infections, pre-eclampsia). The age range is whatever the mother is — but the screening intensity is the same regardless.
Primary sources
Further reading
- HCT/PThe category birth tissue lives in (when it qualifies).
- 21 CFR 1271The regulation governing birth-tissue establishments.
- AATB StandardsBirth-tissue-specific accreditation.
- Donor EligibilityLiving-donor eligibility for birth-tissue recovery.
- Blood & Tissue Industry ViewBirth tissue in the V5 floor workflow.
Explore this topic
Birth Tissue sits inside this topic cluster in our glossary. Every neighbour is one click away.
HCT/Ps, blood cGMP, donor eligibility, ISBT 128 labeling and forward-tracing lookback.
Want to see how Birth Tissue could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.